Get the Stockscreener App
1.23
0.81%
-0.01
After Hours:
1.17
-0.06
-4.88%
Galectin Therapeutics Inc stock is traded at $1.23, with a volume of 692.23K.
It is down -0.81% in the last 24 hours and up +18.27% over the past month.
See More
Previous Close:
$1.24
Open:
$1.24
24h Volume:
692.23K
Relative Volume:
1.03
Market Cap:
$67.78M
Revenue:
-
Net Income/Loss:
$-41.07M
P/E Ratio:
-1.6622
EPS:
-0.74
Net Cash Flow:
$-32.97M
1W Performance:
+6.96%
1M Performance:
+18.27%
6M Performance:
-49.17%
1Y Performance:
-29.71%
1-Day Range:
$1.11
$1.24
1-Week Range:
$1.11
$1.29
52-Week Range:
$0.726
$4.2684
Galectin Therapeutics Inc Stock (GALT) Company Profile
Name
Galectin Therapeutics Inc
Sector
Industry
Phone
678-620-3186
Address
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
Compare GALT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
1.23 | 67.78M | 0 | -41.07M | -32.97M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-20 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-19 | Initiated | B. Riley FBR | Buy |
| Dec-07-17 | Reiterated | H.C. Wainwright | Buy |
| Nov-28-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-19-17 | Initiated | ROTH Capital | Buy |
| Mar-30-17 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-03-16 | Downgrade | FBR & Co. | Outperform → Mkt Perform |
| Sep-29-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-28-16 | Downgrade | ROTH Capital | Buy → Sell |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Sep-21-15 | Initiated | H.C. Wainwright | Buy |
| Aug-01-14 | Downgrade | Aegis Capital | Buy → Hold |
| Jul-30-14 | Reiterated | MLV & Co | Buy |
| Jul-29-14 | Reiterated | MLV & Co | Buy |
| Apr-02-14 | Reiterated | MLV & Co | Buy |
| Feb-10-14 | Reiterated | Aegis Capital | Buy |
| Jan-09-14 | Reiterated | Aegis Capital | Buy |
| Dec-03-13 | Initiated | MLV & Co | Buy |
| Aug-19-13 | Reiterated | Aegis Capital | Buy |
View All
Galectin Therapeutics Inc Stock (GALT) Latest News
Galectin Therapeutics (NASDAQ: GALT) Updates Corporate Presentation and Discloses Forward-Looking StatementsGalectin Therapeutics Inc. (the “Company”) updated its corporate presentation on January 13, 2025, which will be utilized in interactions such - Defense World
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Purchased by Wealth Enhancement Advisory Services LLC - Defense World
Galectin Therapeutics Target of Unusually High Options Trading (NASDAQ:GALT) - MarketBeat
Comparing Galectin Therapeutics (NASDAQ:GALT) and Avenue Therapeutics (NASDAQ:ATXI) - Defense World
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference - The Manila Times
Galectin Therapeutics to Present Breakthrough NAVIGATE Trial Results at MASH-TAG 2025 Conference - StockTitan
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by Barclays PLC - Defense World
Geode Capital Management LLC Acquires 20,817 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Bought by State Street Corp - Defense World
Galectin Therapeutics director Harold Shlevin purchases $7,539 in common stock - Investing.com Nigeria
Galectin Therapeutics Director Increases Stake Amid Strong Momentum, Despite Trial Setbacks - HPBL
Galectin Therapeutics (NASDAQ:GALT) Lowered to “Sell” Rating by StockNews.com - Defense World
Galectin Therapeutics (NASDAQ:GALT) Downgraded by StockNews.com to "Sell" - MarketBeat
Galectin Therapeutics Inc. (NASDAQ:GALT) Short Interest Up 41.1% in December - MarketBeat
North American Morning Briefing : Boeing Stock -2- - Marketscreener.com
Galectin Therapeutics Inc. (NASDAQ:GALT) Shares Sold by Sanctuary Advisors LLC - Defense World
H.C. Wainwright cuts Galectin stock rating to Neutral By Investing.com - Investing.com Canada
Galectin Therapeutics (NASDAQ:GALT) Given “Neutral” Rating at HC Wainwright - Defense World
HC Wainwright & Co. Downgrades Galectin Therapeutics (GALT) - MSN
HC Wainwright Reiterates Neutral Rating for Galectin Therapeutics (NASDAQ:GALT) - MarketBeat
Eldred Kary buys $11,044 in Galectin Therapeutics shares By Investing.com - Investing.com Australia
Joel Lewis Sells 56,000 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) Stock - MarketBeat
Insider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Insider Sells 13,654 Shares of Stock - MarketBeat
Galectin Therapeutics Inc. (NASDAQ:GALT) CFO Sells $35,600.00 in Stock - MarketBeat
Eldred Kary buys $11,044 in Galectin Therapeutics shares - Investing.com India
Galectin Therapeutics director Kevin Freeman acquires $8,134 in stock By Investing.com - Investing.com Australia
Galectin Therapeutics director Kevin Freeman acquires $8,134 in stock - Investing.com India
Galectin Therapeutics CEO Lewis Joel sells $49,610 in stock By Investing.com - Investing.com Canada
Galectin Therapeutics director Richard Zordani buys $8,164 in stock By Investing.com - Investing.com Nigeria
Galectin Therapeutics’ chief medical officer sells $12,044 in shares By Investing.com - Investing.com Nigeria
Galectin Therapeutics director Richard Zordani buys $8,164 in stock - Investing.com India
Galectin therapeutics CFO Jack Callicutt sells $35,492 in stock By Investing.com - Investing.com Canada
Galectin Therapeutics CEO Lewis Joel sells $49,610 in stock - Investing.com
Galectin Therapeutics' chief medical officer sells $12,044 in shares - Investing.com
Liver Cirrhosis Therapeutics Market Size in the 7MM was ~USD 3,100 Million in 2023, is further anticipated to increase with a siginificant CAGR by 2034 and estimated DelveInsight - Barchart
Liver Cirrhosis Therapeutics Market Size in the 7MM was ~USD - openPR
Galectin Therapeutics Announces Positive Results from NAVIGATE Clinical Trial - Defense World
Galectin drops as trial for lead asset fails in MASH - MSN
Belapectin shows promise in liver disease trial - Investing.com India
Dow Surges Over 600 Points, Gold Jumps 1.5% - Benzinga
Galectin Therapeutics Shares Drop 54% After Treatment Misses Trial Endpoint - MarketWatch
Nasdaq Jumps Over 300 Points, Novo Nordisk Shares Spike Higher - Benzinga
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Galectin Therapeutics stock hits 52-week low at $1.23 - Investing.com
Phase III MASH Miss Sends Galectin Stock Tumbling - BioSpace
Dow Surges 100 Points, Carnival Earnings Top Views - Benzinga
Galectin Therapeutics stock hits 52-week low at $1.23 By Investing.com - Investing.com Nigeria
Belapectin shows promise in liver disease trial By Investing.com - Investing.com South Africa
Galectin stock drops after MASH trial data (GALT:NASDAQ) - Seeking Alpha
Galectin Therapeutics Inc Stock (GALT) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):